WHO Pharmaceuticals Newsletter 2002, No. 03
(2002; 22 pages) Voir le document au format PDF
Table des matières
Fermer ce répertoireREGULATORY MATTERS
Afficher le documentARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid
Afficher le documentARTHRIN, OSPORO, POENA AND OTHERS - Presence of undeclared prescription drugs poses health threat
Afficher le documentASPIRIN - Restrictions on use in children extended to teenagers
Afficher le documentBACLOFEN - Life threatening sequelae and/or death with abrupt withdrawal of intrathecal injections
Afficher le documentBEJAI BOWYANTAN - Risk of toxicity in children due to presence of Borneol
Afficher le documentCELECOXIB - CLASS findings added to product label
Afficher le documentEPOETIN-ALFA - Important safety update
Afficher le documentGLITAZONES - strengthens labelling for cardiovascular risks
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - Product information updated
Afficher le documentIRINOTECAN - Labelling updated
Afficher le documentKAVA-KAVA - More withdrawals due to hepatotoxic risks
Afficher le documentMELOXICAM - Additional information in package insert
Afficher le documentMISOPROSTOL - Major labelling changes
Afficher le documentNIMESULIDE - Temporary suspension pending further evaluation
Afficher le documentOLANZAPINE - Risk of hyperglycaemia
Afficher le documentPOOLED PLASMA (HUMAN) SOLVENT DETERGENT TREATED - Boxed warning to indicate new contraindication
Afficher le documentPROPOFOL - Contraindication section modified
Afficher le documentROFECOXIB - Reports of gastrointestinal/cardio vascular toxicity; labelling updated
Afficher le documentSIROLIMUS - Correction to drug safety information
Afficher le documentSLIM 10 - Withdrawn due to presence of adulterants
Afficher le documentTAMOXIFEN - Boxed warning added to product label
Afficher le documentTETRABAMATE - Withdrawal due to reports of hepatotoxicity
Afficher le documentVALPROATE - Labelling strengthened
Afficher le documentZONISAMIDE - Prescribing information updated
Ouvrir ce répertoire et afficher son contenuSAFETY OF MEDICINES
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
Afficher le documentEVENTS & ANNOUNCEMENTS
 

ARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid

Canada.

Health Canada is advising Canadians not to consume Longdan or Lung Tan Xi Gan products since they may contain herbs with aristolochic acid. Aristolochic acid is considered carcinogenic and has been shown to cause mutations in human cells and end-stage kidney failure. Health Canada is working with the manufacturers, distributors and importers to recall these products in Canada. A customs alert has also been issued, to prevent the importation of these products into Canada. Health Canada first issued a warning on aristolochic acid in November 1999 that this ingredient posed a Class I Health Hazard with a potential to cause serious health effects or death.

Readers are referred to previous issues of the WHO Pharmaceuticals Newsletter (Nos. 2&3, 2001; Issue No. 1, 2002; Issue No. 2, 2002) for earlier reports on safety and regulatory measures on aristolochic acid-containing products in other countries.

Reference:

Health Canada Warnings/Advisories, 16 May 2002. Available from URL: http://www.hc-sc.gc.ca

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013